Alnylam Pharmaceuticals (ALNY) Capital Expenditures (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Capital Expenditures came in at $34.7 million in Q2 2026, up 142.64% YoY from $14.3 million in Q2 2025, and up 58.84% on a QoQ basis from $21.8 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Capital Expenditures (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Capital Expenditures data on file, last reported at $34.7 million in Q2 2026.
- Quarterly Capital Expenditures rose 142.64% year-over-year to $34.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $91.9 million (up 151.57% YoY) and the FY2025 annual result came in at $58.7 million, up 71.24% from the prior year.
- Capital Expenditures improved to $34.7 million in Q2 2026, from $21.8 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $34.7 million in Q2 2026 to a low of $4.2 million in Q3 2024.
- A 5-year average of $15.8 million and a median of $15.6 million in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2024 — Capital Expenditures plunged 75.47% — and 2025, when it soared 189.65%.
- Tracing ALNY's Capital Expenditures over 5 years: stood at $21.6 million in 2022, then declined by 29.24% to $15.3 million in 2023, then plunged by 40.6% to $9.1 million in 2024, then jumped by 156.12% to $23.3 million in 2025, then surged by 48.89% to $34.7 million in 2026.
- The last three Capital Expenditures figures came in at $34.7 million (Q2 2026), $21.8 million (Q1 2026), and $23.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.68 Mn |
| Jun 30, 2026 | 34.68 Mn |
| Mar 31, 2026 | 21.83 Mn |
| Mar 31, 2026 | 21.83 Mn |
| Dec 31, 2025 | 49.09 Mn |
| Dec 31, 2025 | 49.09 Mn |
| Sep 30, 2025 | -13.66 Mn |
| Sep 30, 2025 | -13.66 Mn |
| Jun 30, 2025 | 14.29 Mn |
| Jun 30, 2025 | 14.29 Mn |
| Mar 31, 2025 | 8.97 Mn |
| Mar 31, 2025 | 8.97 Mn |
| Dec 31, 2024 | 9.09 Mn |
| Dec 31, 2024 | 9.09 Mn |
| Sep 30, 2024 | 24.12 Mn |
| Sep 30, 2024 | 24.12 Mn |
| Jun 30, 2024 | -1.18 Mn |
| Jun 30, 2024 | -1.18 Mn |
| Mar 31, 2024 | 2.24 Mn |
| Mar 31, 2024 | 2.24 Mn |